Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 12.39 is in line with its 5-year average of 11.82, around the middle of its 5-year range (4.24–20.87).
As of the fiscal period ended Tuesday, June 30, 2026. 45.98% above its 12-month average of 8.49.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 12.39.
QUICK RATIO (ACID-TEST)
12.39
QUICK RATIO (ACID-TEST) AVG TTM
8.49
QUICK RATIO (ACID-TEST) AVG 3Y
8.06
QUICK RATIO (ACID-TEST) AVG 5Y
11.82
QUICK RATIO (ACID-TEST) AVG 10Y
10.53
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+45.98%
CURRENT VS 3Y AVG
+53.73%
CURRENT VS 5Y AVG
+4.83%
CURRENT VS 10Y AVG
+17.60%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.20
median of 785 covered companies
CURRENT VS SECTOR MEDIAN
+287.08%
vs the sector median at left
Ovid Therapeutics Inc.
Market Cap
$447.00M
Quick Ratio (Acid-Test)
12.39
TTM Avg
8.49
3Y Avg
8.06
5Y Avg
11.82
Market Cap
$448.85M
Quick Ratio (Acid-Test)
6.72
TTM Avg
10.04
3Y Avg
13.74
5Y Avg
16.43
Market Cap
$444.90M
Quick Ratio (Acid-Test)
3.91
TTM Avg
4.41
3Y Avg
5.46
5Y Avg
6.71
Market Cap
$440.53M
Quick Ratio (Acid-Test)
7.35
TTM Avg
8.39
3Y Avg
5.06
5Y Avg
6.73
Market Cap
$437.61M
Quick Ratio (Acid-Test)
13.99
TTM Avg
3.82
3Y Avg
4.27
5Y Avg
5.98
Market Cap
$434.82M
Quick Ratio (Acid-Test)
3.19
TTM Avg
3.65
3Y Avg
4.66
5Y Avg
6.11
Market Cap
$429.62M
Quick Ratio (Acid-Test)
3.35
TTM Avg
2.92
3Y Avg
4.56
5Y Avg
5.25
Market Cap
$468.74M
Quick Ratio (Acid-Test)
4.67
TTM Avg
9.07
3Y Avg
10.56
5Y Avg
11.63
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | $447.00M | 12.39 | 8.49 | 8.06 | 11.82 |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $448.85M | 6.72 | 10.04 | 13.74 | 16.43 |
| NeuroPace, Inc. (NPCE)vs › | $444.90M | 3.91 | 4.41 | 5.46 | 6.71 |
| Capricor Therapeutics, Inc. (CAPR)vs › | $440.53M | 7.35 | 8.39 | 5.06 | 6.73 |
| Assembly Biosciences, Inc. (ASMB)vs › | $437.61M | 13.99 | 3.82 | 4.27 | 5.98 |
| NRC Health (NRC)vs › | $456.59M | 0.65 | 0.55 | 0.77 | 1.10 |
| Editas Medicine, Inc. (EDIT)vs › | $434.82M | 3.19 | 3.65 | 4.66 | 6.11 |
| NeoGenomics, Inc. (NEO)vs › | $429.62M | 3.35 | 2.92 | 4.56 | 5.25 |
| Sight Sciences, Inc. (SGHT)vs › | $468.74M | 4.67 | 9.07 | 10.56 | 11.63 |
| Contineum Therapeutics, Inc. (CTNM)vs › | $468.38M | 37.17 | 24.09 | 19.47 | 19.38 |
Quick Ratio
12.39
Excludes inventory
Current Ratio
12.39
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 12.39 |
| 2026-03-31 | 10.17 |
| 2025-12-31 | 10.91 |
| 2025-09-30 | 4.24 |
| 2025-06-30 | 4.72 |
| 2025-03-31 | 4.93 |
| 2024-12-31 | 5.32 |
| 2024-09-30 | 5.66 |
| 2024-06-30 | 5.73 |
| 2024-03-31 | 10.47 |
| 2023-12-31 | 9.55 |
| 2023-09-30 | 10.59 |
| 2023-06-30 | 10.07 |
| 2023-03-31 | 17.78 |
| 2022-12-31 | 18.79 |
| 2022-09-30 | 20.87 |
| 2022-06-30 | 16.94 |
| 2022-03-31 | 16.63 |
| 2021-12-31 | 12.87 |
| 2021-09-30 | 20.37 |
| 2021-06-30 | 19.12 |
| 2021-03-31 | 14.48 |
| 2020-12-31 | 3.39 |
| 2020-09-30 | 5.03 |
| 2020-06-30 | 3.02 |
| 2020-03-31 | 6.08 |
| 2019-12-31 | 7.58 |
| 2019-09-30 | 3.78 |
| 2019-06-30 | 5.84 |
| 2019-03-31 | 7.78 |
| 2018-12-31 | 5.01 |
| 2018-09-30 | 5.30 |
| 2018-06-30 | 8.70 |
| 2018-03-31 | 11.50 |
| 2017-12-31 | 14.71 |
| 2017-09-30 | 21.02 |
| 2017-06-30 | 15.19 |
| 2017-03-31 | 9.56 |
| 2016-12-31 | 13.97 |
| 2016-09-30 | 21.76 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 30.44 |
